Početna › Folikularni limfom › Washington › Seattle
Kliničke studije za Folikularni limfom u gradu Seattle, WA
15 studija za Folikularni limfom traži sudionike na lokacijama u gradu Seattle i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
U tijeku regrutacijaFaza 1/2
- Research Site, Seattle
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
U tijeku regrutacijaFaza 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
U tijeku regrutacijaFaza 1
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
U tijeku regrutacijaFaza 1
- Swedish Cancer Institute (SCI), Seattle
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
U tijeku regrutacijaFaza 1/2
- Fred Hutchinson Cancer Research Center, Seattle
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
U tijeku regrutacijaFaza 3
- Fred Hutch Cancer Center, Seattle
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
U tijeku regrutacijaFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
U tijeku regrutacijaFaza 1
- Fred Hutchinson Cancer Center, Seattle
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
U tijeku regrutacijaFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
U tijeku regrutacijaFaza 2Zdravi dobrovoljci dobrodošli
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
U tijeku regrutacijaFaza 1
- Fred Hutchinson Cancer Center, Seattle
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
U tijeku regrutacijaFaza 1/2
- University of Washington-Seattle Cancer Care Alliance, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
U tijeku regrutacijaOpažajna studija
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
U tijeku regrutacijaFaza 1
- Swedish Cancer Institute, Seattle
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
U tijeku regrutacija
- University of Washington Medical Center, Seattle
Studije za Folikularni limfom u drugim gradovima
- New York City, NY24 studija
- Milwaukee, WI19 studija
- Nashville, TN18 studija
- Houston, TX18 studija
- Boston, MA17 studija
- Baldwin Park, CA16 studija
- Durham, NC15 studija
- Columbus, OH13 studija
- Salt Lake City, UT13 studija
- San Antonio, TX12 studija
- Chicago, IL12 studija
- Philadelphia, PA12 studija
Ostale studije u gradu Seattle
- Nemikrocelularni karcinom pluća53 studija
- Rak (sve vrste)49 studija
- Rak prostate42 studija
- Akutna mijeloična leukemija40 studija
- Rak dojke39 studija
- Metastatski karcinom39 studija
- Kolorektalni rak34 studija
- Rak pluća33 studija
- Rak jajnika30 studija
- Multipli mijelom22 studija
- Mijelodisplastični sindromi21 studija
- Akutna limfoblastna leukemija21 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.